Δnp63 (p40) distribution inside lung cancer: A driver biomarker approach to tumor characterization

International Journal of Surgical Pathology

Volumn 21, Issue 3, 2013, Pages 229-239

  Pelosi, Giuseppe ^a,b   Rossi, Giulio ^c   Cavazza, Alberto ^c   Righi, Luisella ^d   Maisonneuve, Patrick ^e   Barbareschi, Mattia ^f   Graziano, Paolo ^g   Pastorino, Ugo ^a   Garassino, Marina ^a   De Braud, Filippo ^a   Papotti, Mauro ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d SAN LUIGI GONZAGA HOSPITAL   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f SANTA CHIARA HOSPITAL   (Italy)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

diagnosis; immunohistochemistry; lung cancer; p40; p63; TTF1

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P40; THYROID TRANSCRIPTION FACTOR 1;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CARCINOID; CARCINOSARCOMA; CELL DIFFERENTIATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; SALIVARY GLAND CANCER;

DIAGNOSIS; IMMUNOHISTOCHEMISTRY; LUNG CANCER; P40; P63; TTF1;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SQUAMOUS CELL; CARCINOSARCOMA; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SMALL CELL LUNG CARCINOMA; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84878225629     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896913476750     Document Type: Article

References (48)

1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011 ; 12: 175-180
2. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 ; 379: 823-832
3. Pelosi G, Pasini F, Olsen Stenholm C, et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?. J Pathol. 2002 ; 198: 100-109
4. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A. 2000 ; 97: 5462-5467
5. Wang BY, Gil J, Kaufman D, et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol. 2002 ; 33: 921-926
6. Rossi G, Pelosi G, Graziano P, Barbareschi M, Papotti M. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009 ; 17: 206-218
7. Rossi G, Papotti M, Barbareschi M, Graziano P, Pelosi G. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol. 2009 ; 27: e141-142
8. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009 ; 22: 709-717
9. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011 ; 117: 3416-3423
10. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012 ; 25: 405-415
11. Pelosi G, Fabbri A, Bianchi F, et al. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 2012 ; 7: 281-290
12. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011 ; 24: 1348-1359
13. Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol. 2011 ; 6: 1039-1049
14. Hibi K, Nakayama H, Taguchi M, et al. AIS overexpression in advanced esophageal cancer. Clin Cancer Res. 2001 ; 7: 469-472
15. Okuyama R, Ogawa E, Nagoshi H, et al. p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity. Oncogene. 2007 ; 26: 4478-4488
16. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998 ; 2: 305-316
17. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999 ; 398: 714-718
18. Chilosi M, Poletti V, Murer B, et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest. 2002 ; 82: 1335-1345
19. Morbini P, Inghilleri S, Campo I, et al. Incomplete expression of epithelial-mesenchymal transition markers in idiopathic pulmonary fibrosis. Pathol Res Pract. 2011 ; 207: 559-567
20. Romano RA, Ortt K, Birkaya B, Smalley K, Sinha S. An active role of the ΔN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One. 2009 ; 4: e5623
21. King KE, Ponnamperuma RM, Gerdes MJ, et al. Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis. Carcinogenesis. 2006 ; 27: 53-63
22. Romano RA, Smalley K, Magraw C, et al. ΔNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development. 2012 ; 139: 772-782
23. Nekulova M, Holcakova J, Coates P, Vojtesek B. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett. 2011 ; 16: 296-327
24. Karni-Schmidt O, Castillo-Martin M, Shen TH, et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol. 2011 ; 178: 1350-1360
25. Yang X, Lu H, Yan B, et al. ΔNp63 versatilely regulates a Broad NF-kappaB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res. 2011 ; 71: 3688-700
26. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, et al. ΔNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009 ; 15: 6284-6291
27. Stelow EB, Bellizzi AM, Taneja K, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008 ; 32: 828-834
28. Boldrup L, Coates PJ, Gu X, Nylander K. ΔNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target. J Pathol. 2009 ; 218: 428-436
29. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012 ; 18: 1167-1176
30. Uramoto H, Yamada S, Hanagiri T. Immunohistochemical staining with ΔNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res. 2010 ; 30: 4717-4720
31. Pelosi G, Sonzogni A, Papotti M, et al. Different prevalence of transactivating (TA) p63 and non-TAp63 isoforms in pulmonary adenocarcinomas: a useful diagnostic tool. Mod Pathol. 2010 ; 23: 396A - 415A
32. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell lung carcinomas of the lung. Am J Surg Pathol. 2001 ; 25: 363-372
33. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 2010 ; 29: 23-36
34. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002 ; 26: 767-773
35. Travis W, Brambilla E, Muller-Hermelink H, Harris C Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press ; 2004 :
36. Travis W, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 ; 6: 244-285
37. Sobin L, Gospodarowicz M, Wittekind C TNM Classification of Malignant Tumours. New York, NY: Wiley-Blackwell ; 2010 :
38. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010 ; 34: 1155-1162
39. Pelosi G, Melotti F, Cavazza A, et al. A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples. Anticancer Res. 2012 ; 32: 1463-1473
40. Nonaka D. A study of Δnp63 expression in lung non-small cell carcinomas. Am J Surg Pathol. 2012 ; 36: 895-899
41. Barbareschi M, Cantaloni C, Del Vescovo V, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol. 2011 ; 136: 773-782
42. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, Napsin A, p63, and CK5/6. Am J Surg Pathol. 2011 ; 35: 15-25
43. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010 ; 34: 1805-1811
44. Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol. 2010 ; 18: 103-120
45. Pardo J, Martinez-Penuela AM, Sola JJ, et al. Large cell carcinoma of the lung: an endangered species?. Appl Immunohistochem Mol Morphol. 2009 ; 17: 383-392
46. Molina JR, Aubry MC, Lewis JE, et al. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer. 2007 ; 110: 2253-2259
47. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006 ; 24: 1679-1688
48. Lo Iacono M, Monica V, Saviozzi S, et al. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. J Thorac Oncol. 2011 ; 6: 473-481